 |
      
|
|
|
|
|
|||||
|
|
September 23, 2004
Neurochem to present at 2004 UBS Global Life Sciences Conference and at CIBC World Markets Frontenac
Institutional Investor Conference. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs.
Fibrillex™, designated as an orphan drug and as a Fast Track Product candidate, is also part of a Continuous
Marketing Applications Pilot 2 program and is currently in a Phase II/III clinical trial for the treatment of AA
Amyloidosis. Alzhemed™, for the treatment of Alzheimer's Disease, is in a Phase III clinical trial and Cerebril™,
for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase II clinical
trial.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at
the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations
of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond
Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general
conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation as well as other risks included in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the forward-looking statements. The reader should
not place undue reliance on any forward-looking statements included in this news release. These statements speak only
as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
